Bone Biologics Corporation BBLG
0.29 USD -0.02 (-5.92%)
Regular-session close
0.29 0.00 -0.86%
After hours · Nov 18, 5:17 PM ET
0.2811 Day range 0.3168
0.266 52-week range 2.39
- YTD
- -79.93%
- 1 year
- -82.15%
News
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 74.0% to $5.03 during Thursday's pre-market session. ZeroStack (NASDAQ:ZSTK) stock increased by 11.56% to $2.99. The market value of their…benzinga.com Bone Biologics Q3 EPS $(0.17) Beats $(0.18) Estimate Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 54.05 percent increase over losses of…
defenseworld.net Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Drops By 76.4% Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 36,999 shares, a decrease of…
globenewswire.com Bone Biologics Expands Trial Sites BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion…
globenewswire.com Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion…
globenewswire.com Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1 BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion…
defenseworld.net Bone Biologics (BBLG) to Announce Earnings on Thursday Bone Biologics (NASDAQ: BBLG - Get Free Report) will likely be issuing its results before the market opens on Thursday, August 13th. Analysts expect Bone Biologics to announce earnings of ($0.39) per…
globenewswire.com Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion…
globenewswire.com Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash $3.0 million upfront with up to approximately $6.0…
globenewswire.com Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance Key accomplishments include expanded rhNELL-1 shelf…
globenewswire.com Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months Milestone advances manufacturing readiness and supports long-term commercialization strategy Milestone advances manufacturing readiness and supports long-term commercialization strategy
defenseworld.net Bone Biologics (NASDAQ:BBLG) Shares Down 0.5% – Should You Sell? Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report)'s share price fell 0.5% during trading on Wednesday. The stock traded as low as $1.9246 and last traded at $2.10. 43,801 shares were traded…
businesswire.com Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces…
businesswire.com Bone Biologics Announces Closing of $5.0 Million Public Offering BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today…
benzinga.com Why Is Bone Biologics Stock Surging On Friday? Bone Biologics Corporation BBLG stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K as per data from Benzinga Pro.
businesswire.com Bone Biologics Announces Pricing of $5.0 Million Public Offering BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today…
businesswire.com Bone Biologics Files Patent Application for Bone Regeneration Technology BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #Bonebiologics--Bone Biologics files U.S. patent application for bone regeneration technology.
businesswire.com Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today…
businesswire.com Bone Biologics Announces 1-for-6 Reverse Stock Split BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today…
businesswire.com Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today…
businesswire.com First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces…
